Atlas Trials

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

Clinical trial NCT04397601 · UNKNOWN

Trial details

NCT number
NCT04397601
Sponsor
National Cancer Institute, Naples
Status
UNKNOWN
Study type
OBSERVATIONAL
Metastatic Colorectal Cancer
Start date
2020-05-11
Primary completion
2023-05-11
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.